Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
- October 22, 2009
- Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
- July 24, 2009
- Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
- April 20, 2009
- Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
- February 11, 2008
- Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
- November 3, 2007
- Vaccinogen Announces Completion of its Initial Capitalization Plan
- October 1, 2007
- Vaccinogen Announces Formation of Company
- July 19, 2006
- FDA Grants Special Protocol Assessment
Frederick, MD, USA – October 22, 2009 – Vaccinogen, Inc. announces that it has entered into a letter of intent with Durham, NC-based Clinipace Worldwide to manage its pivotal Phase III trial for OncoVAX® which treats Stage II Colon Cancer.
“Vaccinogen selected Clinipace Worldwide for its upcoming global clinical trial due, in part, to the combined strength of both companies and experience managing phase 3 international oncology trials," said Michael G. Hanna, Jr., Ph.D., Founder, Chairman & CEO of Vaccinogen. “We are confident its therapeutic and operations experts, along with its technology platform, will enable us to centrally manage a very complex protocol with some very unique requirements.”
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth “booster” is administered six months later. OncoVAX® reduces recurrence and deaths by over 50%.
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, antiinflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX® vaccines.
About Clinipace Worldwide
Clinipace Worldwide is a global technology-driven clinical research organization (CRO) specializing in fully integrated research services for growth-oriented and mid-tier biopharmaceutical and medical device firms. With specific expertise in oncology, among other therapeutic areas, Clinipace Worldwide has managed over 70 contract research projects conducted at almost 3,000 sites with 100,000 patients. Clinipace Wordwide is headquartered in Research Triangle Park, NC with additional domestic operations in Overland Park, KS, and American operations based in Brazil, Argentina and Peru.
Contact:
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400